MHRA
Market Access/ News/ News/ News/ Patients
UK grants early access to Argenx’ efgartigimod for myasthenia gravis
Phil Taylor
access, Argenx, efgartigimod, MHRA, myasthenia gravis, patients, rare disease, UK, Vyvgart
0 Comment
UK grants early access to Novartis’ prostate cancer radioligand
Phil Taylor
Advanced Accelerator Applications, Early Access to Medicines Scheme, MHRA, Novartis, Pluvicto, Prostate cancer, Radiopharmaceutical, UK
0 Comment
EU regulator backs Idorsia’s Quviviq for adults with insomnia
Joy Persaud
CHMP, EU, Idorsia, insomnia, market access, MHRA, pharma
0 Comment
Novavax COVID jab ‘could save UK money on boosters’
Phil Taylor
coronavirus, COVID-19, COVID-19 vaccine, MHRA, Novavax, UK
0 Comment
MHRA seeks comments on post-Brexit clinical trial legislation
Phil Taylor
Brexit, clinical trials, MHRA, regulatory
0 Comment
UK green lights Gilead Sciences, Galapagos ulcerative colitis drug
Joy Persaud
Galapagos, Gilead, market access, MHRA, pharma
0 Comment
MHRA okays GSK’s Xevudy as data suggest it works against Omicron
Phil Taylor
antibody, coronavirus, COVID-19, GlaxoSmithKline, MHRA, regulatory approval, sotrovimab, Vir Biotechnology, xevudy
0 Comment